【Asset for Licensing】Novel pan-RAS molecular glue degrader for multiple solid tumors

Asset: Novel pan-RAS molecular glue degrader
Development Stage: IND enabling stage
Indication: Multiple solid tumors
Key Asset Highlights:
（1）Adopts an innovative molecular glue mechanism of action, targeting and inducing the degradation of widespread RAS isoforms to block aberrant RAS-driven signaling, overcoming the technical bottleneck of traditional RAS-targeted therapies.
（2）Exerts potent pan-RAS inhibitory and degradation activity against major RAS mutants including KRAS, HRAS and NRAS, producing robust anti-proliferative effects across diverse RAS-mutant solid tumor models.
（3）Effectively ablates downstream oncogenic signaling cascades, inducing significant tumor cell cycle arrest and apoptosis, and demonstrating broad-spectrum in vivo anti-tumor efficacy in refractory solid tumors.
（4）Possesses prominent differentiated advantages over isoform-specific RAS inhibitors, capable of addressing cross-mutational drug resistance and covering a wider patient population with unmet clinical needs.
（5）Features optimized physicochemical properties and favorable pharmacokinetic profiles, supporting efficient systemic exposure and further clinical translation for solid tumor treatment.
（6）Backed by a comprehensive global intellectual property portfolio, securing exclusive and stable worldwide development and commercialization rights for pan-RAS targeted solid tumor therapy.

If you are a Search & Evaluation professional working at an MNC, biopharma, biotech or VC, and are interested in this opportunity, please feel free to contact the DrugTimes BD Team.

Email: BD@drugtimes.cn

Thank you very much!

【Disclaimer】All information presented above and on this website is provided for informational purposes only. We make no guarantee as to its accuracy, completeness or timeliness. Readers shall exercise caution when referencing the content.